Piper Sandler on Natera (NTRA): 'IMvigor011 Changes the Game in More Ways than Expected'

Piper Sandler analyst Dave Westenberg reiterated an Overweight rating and $220.00 price target on Natera (NASDAQ: NTRA).

The analyst commented: "IMvigor011 Changes the Game in More Ways than Expected; Last month, Natera announced positive results from its IMvigor011 trial. We believe the trial represents a major step forward in MRD testing. First, the clinical trial was the first to show MRD negative with better "overall survival" a key measure in oncology. Secondly, MRD use was tied to a specific drug. This should lead to more clinical trial in other histology, where actual clinicians would publish on MRD being used for a therapeutic decision. Lastly, we believe this shows the power of Natera's database. Natera has the power to find patients associated with relapse, which makes it a powerful partner to pharma."

For an analyst ratings summary and ratings history on Natera click here. For more ratings news on Natera click here.

Shares of Natera closed at $168.45 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Aurora Spine settles patent dispute, secures $600K insider loan
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)